Trial Profile

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms NabucCO

20 Jan 2018 Results (n=84) assessing efficacy and tolerability of first-line therapy with paclitaxel + irinotecan + folinic acid + fluorouracil (FOLFIRI), versus paclitaxel + oxaliplatin + folinic acid + fluorouracil (FOLFOX), in patients with metastatic pancreatic cancer, were presented at the 2018 Gastrointestinal Cancers Symposium.
02 Feb 2017 Status changed from recruiting to completed.
11 Oct 2016 Results of Phase I portion (n=63) of study presented at the 41st European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com